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Infection of macaques with chimeric viruses based
on SIVMAC but expressing the HIV-1 envelope (Env)
glycoproteins (SHIVs) remains the most powerful
model for evaluating prevention and therapeutic
strategies against AIDS. Unfortunately, only a few
SHIVs are currently available. Furthermore, their
generation has required extensive adaptation of the
HIV-1 Env sequences in macaques so they may not
accurately represent HIV-1 Env proteins circulating
in humans, potentially limiting their translational
utility. We developed a strategy for generating large
numbers of SHIV constructs expressing Env proteins
from newly transmitted HIV-1 strains. By inoculating
macaques with cocktails of multiple SHIV variants,
we selected SHIVs that can replicate and cause
AIDS-like disease in immunologically intact rhesus
macaques without requiring animal-to-animal pas-
sage. One of these SHIVs could be transmitted mu-
cosally. We demonstrate the utility of the SHIVs
generated by this method for evaluating neutralizing
antibody administration as a protection against
mucosal SHIV challenge.
INTRODUCTION
The recent identification of antibodies that potently neutralize
diverse HIV-1 strains has renewed enthusiasm for the develop-
ment of antibody-based prevention and therapeutic strategies
(Burton et al., 2012; Klein et al., 2013). Nonhuman primates
such as macaques offer an immunologically intact model and412 Cell Host & Microbe 16, 412–418, September 10, 2014 ª2014 Elcan succumb to AIDS-like disease when infected with simian
immunodeficiency viruses such as SIVMAC (Hatziioannou and
Evans, 2012). However, the large genetic distance between
SIV and HIV-1 is an important limitation of SIV/macaque models.
Sequence variation obviously affects the nature and specificity
of immunological responses, and neutralizing antibodies against
HIV-1 envelope (Env) proteins are not generally crossreactive
with SIVMAC Env proteins. In an effort to overcome such limita-
tions, chimeric viruses based on SIV but expressing HIV-1 Env
and certain HIV-1 accessory genes, (SHIVs) have been gener-
ated. Although there is concern that protection against some
of the first SHIVs is too easily achieved with vaccine candidates,
such viruses remain the best model to guide the design
and in vivo testing of numerous vaccine candidates that raise im-
mune responses against HIV-1 proteins (Hatziioannou and
Evans, 2012).
Thus far, the generation of SHIVs that reflect the CCR5 core-
ceptor preference and pathogenicity of HIV-1 has been slow,
and despite many years of research, there are currently only a
few such SHIVs that are widely used. Moreover, their generation
has required multiple animal-to-animal passages, resulting in
extensive adaptation of the HIV-1 Env sequences (Harouse
et al., 2001; Nishimura et al., 2010; Song et al., 2006), and thus
they have significantly diverged from their HIV-1 counterparts
circulating in humans.
Recent evidence shows that following sexual transmission
of HIV-1 in humans, systemic infection is typically established
by a single transmitted/founder (T/F) viral variant (Keele et al.,
2008; Salazar-Gonzalez et al., 2008; Zhang et al., 1993; Zhu
et al., 1993). T/F viruses may differ in their biological proper-
ties from viruses typically isolated later in HIV-1 infection
(Liao et al., 2013; Parker et al., 2013). Importantly, T/F Env
proteins represent clinically relevant targets that neutralizing
antibodies and inhibitors need to engage to prevent infec-
tion. SHIV chimeras expressing T/F Env proteins would thussevier Inc.
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Figure 1. Cloning Strategy and In Vitro Replication of R5-SHIVs
(A) Flowchart of the strategy used for cloning and screening R5-SHIVs. Restriction sites used to introduce the Env PCRproducts and ligate the two genome halves
are noted.
(B) Replication of SHIVs encoding the indicated Env proteins in MT2 cells engineered to express CCR5. Infectious virus in supernatant samples collected from
MT2-R5 cells at the indicated times p.i. was measured using TZM-bl cells. Results from a representative experiment (of two performed) are shown. See also
Figure S1 and Table S1.
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prophylactic and treatment interventions targeting HIV-1 Env
proteins.
Herein, we have established a strategy for generating and
screening large numbers of SHIVs expressing HIV-1 Env pro-
teins from newly transmitted viruses. SHIVs selected by our
approach were capable of replicating efficiently and causing
AIDS-like disease in immunologically intact rhesus macaques.
We further demonstrate that one of these SHIVs can be trans-
mitted mucosally and can be used to evaluate immunoprophy-
lactic interventions using broadly neutralizing antibodies.
RESULTS
Generation and In Vitro Characterization of a SHIV
Library
We optimized a cloning strategy that allowed the introduction of
Env sequences from clade BHIV-1 strains into a proviral plasmid
based on SHIVKB9, a virus clone derived after in vivo passage
(Karlsson et al., 1997) (Figures 1A; Figure S1A available online).
We pooled distinct clones generated using this approach into
two groups of SHIVs. Group 1 consisted of 21 SHIV clones
expressing Env proteins from R5-tropic T/F clade B viruses
(Keele et al., 2008) (B.F.K. and G.M.S., unpublished data; Table
S1). Group 2 consisted of 16 SHIVs expressing Env sequences
obtained from patient lymphocyte samples taken early (28–
63 days) after infection and prior to any antiretroviral treatment
from a cohort of men who have sex with men. We confirmed
that SHIVs expressing Env proteins that had not been previously
tested were R5-tropic (Figure S1B) and that all SHIVs were repli-
cation competent in MT2 cells engineered to express CCR5
(Figure 1B).Cell Host & MIn Vivo Replication and Selection of R5-SHIVs
To select SHIVs that replicated best in vivo, two rhesus ma-
caques were each inoculated intravenously with a cocktail
containing 2.5 3 104 i.u. (as measured on TZM-bl cells) of
each Group 1 virus. A third animal was inoculated with a
cocktail containing 5 3 104 i.u of each Group 2 virus. Animals
were depleted of CD8+ cells prior to and 1 week postinocu-
lation (p.i.) to enhance initial virus replication. All animals
developed high levels of acute viremia, reaching >108 viral
RNA copies/ml (Figures 2A and 2B). Pronounced peripheral
and gut-associated lymphoid tissue (GALT) CD4+ T cell
depletion was observed in all animals (Figure S2). Notably,
one animal inoculated with Group 1 viruses and the animal
inoculated with Group 2 viruses rapidly succumbed; the
Group 1 animal was sacrificed at 16 weeks p.i. suffering
from extensive AIDS-defining extranodal B cell lymphoma,
and the Group 2 animal was sacrificed at 13 weeks p.i.
suffering from profound anemia, hypoproteinemia as well as
weight loss, and sustained low CD4+ T cell counts character-
istic of AIDS.
Analysis of Env sequences in plasma revealed that only
one Env clone, 1054, was detectable at week 3 p.i. in both
animals infected with Group 1 viruses (Figure 2C). At later
time points, other Env sequences were also detected, such
as AD17, that had recombined with 1054 sequences to
various extents. Similarly, in the animal inoculated with
Group 2 viruses, a single Env clone, AD081, predominated
throughout all sampling time points (Figure 2D). Overall,
these data suggest that the 1054 and AD081 Env proteins
conferred an advantage over other Env proteins in the
same cocktail, supporting more efficient SHIV replication in
macaques.icrobe 16, 412–418, September 10, 2014 ª2014 Elsevier Inc. 413
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Figure 2. In Vivo Selection of R5-SHIVs
(A and B) Plasma viral load in macaques inoculated with cocktails of SHIVs
from Group 1 (A) or Group 2 (B). Animals were depleted of CD8+ cells at the
time of and 1 week post inoculation. Red x indicates euthanasia due to AIDS.
(C and D) Phylogenetic analysis of Env sequences found in the plasma of
Group 1 (C) or Group 2 (D) SHIV-infected macaques. Black lines represent
unmodified Env sequences from Group 1 or Group 2 viruses inoculated into
animals and colored lines Env sequences obtained from infected animals at
the indicated times p.i. Predominant Env sequences are labeled. See also
Figure S2.
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414 Cell Host & Microbe 16, 412–418, September 10, 2014 ª2014 ElIn Vivo Replication of Individual ‘‘Winner’’ SHIVs
We next determined the ability of individual SHIVs encoding un-
adapted AD081 or 1054 Env proteins to replicate in macaques
without CD8+ cell depletion. SHIVAD081 and SHIV1054 were
each intravenously inoculated into two macaques, all of which
developed high levels of acute viremia (Figures 3A and 3B). Spe-
cifically, peak viremia approached 107–108 viral RNA copies/ml
in SHIVAD081-inoculated animals and was accompanied by
marked GALT CD4+ T cell depletion (Figure 3A). Peripheral
CD4+ T cell numbers decreased substantially during acute infec-
tion and continued to progressively decline. Importantly, one
SHIVAD081-infected animal developed severe Pneumocystis
pneumonia and was euthanized at 25 months p.i. for this
AIDS-defining clinical endpoint. In SHIV1054-inoculated animals
peak viremia reached 107 viral RNA copies/ml and remained
high in one animal (Figure 3B). Although both SHIV1054-inocu-
lated animals showed significant CD4+ T cell depletion in the
GALT, peripheral CD4+ T cells in the animal with the highest
viremia decreased dramatically during acute infection and
continued to decline during the course of infection (Figure 3B).
This animal succumbed to an AIDS-defining opportunistic infec-
tion, severe Pneumocystis pneumonia, and was euthanized at
21.5 months p.i. Thus, both unadapted R5-SHIVs selected
by our strategy were capable of causing AIDS in macaques, a
noteworthy property for R5-SHIVs that had not been adapted
by serial passage in macaques.
Evaluation of Immunoprophylaxis Approaches against
SHIVs Expressing Authentic, Transmitted HIV-1 Env
Proteins
Analysis of the sensitivity of SHIV1054, SHIVAD081, and each of
the other T/F-SHIV variants to several neutralizing antibodies re-
vealed that, like most transmitted HIV-1 strains (Seaman et al.,
2010), all exhibited Tier 2 neutralization properties (Table S2).
We elected to perform a passive immunoprophylaxis experiment
with SHIV1054, since it encodes a precise Env sequence that initi-
ated a virus transmission event in humans.
For these studies, we first determined whether SHIV1054 could
be transmitted to macaques via mucosal challenge, since HIV-1
transmission in humans occurs predominantly at mucosal sites.
Six macaques were inoculated with varying doses of SHIV1054
intrarectally to establish an optimal challenge dose at which all
animals became infected. All animals developed high acute
viremia of between 106 and 107 viral RNA copies/ml (Figure 3C).
Viral replication gradually declined thereafter. Although a sub-
stantial decrease in GALT CD4+ T cells was observed in five
out of six infected animals, peripheral CD4+ T cell decrease
was generally modest and transient (Figure S3). These findings
demonstrate the ability of SHIV1054 to infect macaques viasevier Inc.
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Figure 3. Replication of Individual R5-SHIVs in Macaques
(A) Plasma viremia, CD4+ T cell counts in blood, and CD4+ T cell frequency in the GALT for 2 macaques (one in red and one in black) inoculated intravenously with
2.9 3 105 i.u. of SHIVAD081. Asterisks in bar graphs indicate unavailable samples.
(B) As in (A), except that two macaques were inoculated intravenously with 4.8 3 105 i.u. of SHIV1054.
(C) Plasma viremia for six macaques inoculated intrarectally with varying doses of SHIV1054. Arrows indicate time and colors the dose of viral challenge; white
arrow is 3 3 103 i.u., blue arrow is 3 3 104 i.u., black arrow is 7.4 3 104 i.u., and red arrow is 2.1x105 i.u. See also Figure S3.
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for such mucosal challenges.
We then attempted to protect macaques from infection using
PGT121, a potent, broadly neutralizing candidate prophylactic
and therapeutic monoclonal antibody that targets a glycan-
dependent V3 loop epitope (Julien et al., 2013; Walker et al.,
2011) and has been previously demonstrated to protect ma-
caques against mucosal challenges by a macaque-adapted
SHIV (Moldt et al., 2012). PGT121 neutralized SHIV1054 in vitro
(Figure S4A).
We infused six macaques with PGT121 and six with a control
antibody, both at a dose of 10 mg/kg. Serum antibody levels
peaked 1 day postinfusion (Figure 4A), and plasma obtained
from PGT121-infused animals up to 6 days postinfusion potently
neutralized SHIV1054 in vitro (Figure S3B). One day after antibody
infusion, all macaques were challenged intrarectally with 2.1 3
105 i.u. of SHIV1054. All control animals developed high levels
of acute viremia, reaching peaks of 106–107 viral RNA copies/
ml. In contrast, animals that received PGT-121 infusions did
not develop viremia (Figure 4B). A single plasma viral load
‘‘blip’’ was detected at week 3 or 4 postchallenge in five of six
PGT121-infused animals. However, this likely reflects trace
contamination of the plasma samples since (1) all ‘‘blips’’
occurred in samples from the same collection date, rather than
at the same time after infection, and (2) there was no evidence
of established infection in these animals using other assays,
including quantitative RT-PCR (qRT-PCR) assays of matchedCell Host & Mserum samples, qRT-PCR/PCR assays for PBMC-associated
viral RNA and DNA, and immunoblot analysis (Figures S4C and
S4D; Table S3). Overall, our data demonstrate that PGT121 is
capable of protecting macaques against mucosal challenge
with a SHIV encoding an HIV-1 envelope that mediated HIV-1
transmission in humans.
DISCUSSION
Two major limitations that plague current SHIV models are the
paucity in Env diversity represented and the inconsistency in
pathogenicity exhibited by SHIVs developed to date. To over-
come these limitations, we have designed an approach that (a)
facilitates the generation of a large number of SHIVs by intro-
ducing many different HIV-1 Env proteins into a SHIV backbone
and (b) allows in vivo competition to select Env sequences that
confer the highest replicative capacity in macaques. Using this
approach, we generated and screened 37 new SHIVs and
selected two HIV-1 Env proteins that can support efficient repli-
cation and cause AIDS-like disease inmacaqueswithout animal-
to-animal passage.
The fact that each of the SHIVs selected from the two different
groups of viruses is pathogenic in immunologically intact ma-
caques establishes this approach for identifying HIV-1 Env pro-
teins best suited for generation of SHIVs. It also suggests that the
CD8+ cell depletion performed during the initial selection of these
‘‘winners’’ did not grossly affect the outcome. Even though theicrobe 16, 412–418, September 10, 2014 ª2014 Elsevier Inc. 415
Figure 4. HIV-1 Monoclonal Antibody Pro-
tects against T/F Env Virus Challenge
(A) PGT121 antibody concentration in serum of
animals infused with the antibody on day 1. Day
0 is the day of challenge with SHIV1054. Dotted line
indicates antibody concentration that achieves
90% neutralization of SHIV1054 in vitro.
(B) Plasma viremia in macaques receiving pre-
exposure transfusion of PGT121 or control
monoclonal antibodies at 10 mg/kg, followed by
an intrarectal SHIV1054 challenge using 2.1 3 10
5
i.u. of virus. Animals in both groups are shown in
#1 blue, #2 green, #3 purple, #4 red, #5 black, and
#6 orange. See also Figure S4 and Table S3.
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Transmitted/Founder SHIVsnumber of animals used in these experiments is very small, the
fact that SHIV1054 dominated in 2/2 animals infected with 21
different SHIVs is statistically significant (p = 0.0059). At present,
it is unclear what determinants allowed the ‘‘winner’’ Env pro-
teins to outperform others in their respective groups, and we
did not observe any correlation between ‘‘winning’’ and (1) sensi-
tivity to various antibodies or soluble CD4 (Table S2) or (2) un-
usual characteristics of the patients from which they were
derived (see Supplemental Experimental Procedures). It is also
unclear how many of the other SHIVs would have replicated effi-
ciently in non-CD8+-depleted animals. However, the goal of our
approach was to identify HIV-1 Env proteins best suited for SHIV
development, and as such, it was successful.
All our SHIV variants express HIV-1 Env proteins from viruses
that have successfully mediated human-to-human transmission.
The characteristics that render these Env proteins capable of be-
ing preferentially transmitted between humans from a swarm of
other viruses remain uncertain (Liao et al., 2013; Parker et al.,
2013; Parrish et al., 2012; Sagar et al., 2009; Salazar-Gonzalez
et al., 2009; Wilen et al., 2011). Nevertheless, it is conceivable
that the properties that allow them to successfully infect new hu-
man hosts may improve their ability to perform better in the
context of SHIVs in animals.
Importantly, these viruses should be useful and relevant tools
in determining the efficacy of prophylactic interventions target-
ing HIV-1 Env, because they accurately represent the sequences
that such strategies must target to prevent HIV-1 infection in hu-
mans. Indeed, we show that a single neutralizing monoclonal
antibody against HIV-1 Env can provide protection against
mucosal challenges with a SHIV expressing an authentic T/F
HIV-1 Env, underscoring the potential utility of such interventions
in humans.
EXPERIMENTAL PROCEDURES
Cloning Strategy
Two plasmid vectors, containing the 50 and 30 halves of the SHIVKB9 genome
(Karlsson et al., 1997), were generated using a low copy number plasmid back-
bone (pXf3). Full-length proviral plasmids encoding the different HIV-1 Env
proteins were generated as outlined in Figure 1A and described in detail in
Supplemental Experimental Procedures.
Cell Lines
MT2 cells were obtained from NIH AIDS Reagent Program. Following trans-
duction with anMLV-derived vector based on LPCX (Clontech) that expressed
humanCCR5 and selection with puromycin, a single cell clone expressing high416 Cell Host & Microbe 16, 412–418, September 10, 2014 ª2014 Ellevels of CCR5, as determined by FACS using a monoclonal anti-CCR5 anti-
body conjugated to PE (clone 3A9, BD Pharmigen), was selected for use in
all experiments.
Tropism Assays
TZM-bl cells seeded at 83 103 cells/well in 96-well plates the day before were
incubated for 30 min in 100 ml of medium containing Maraviroc (16 mM) or
AMD3100 (2 mM) or no inhibitor. Subsequently, dilutions of SHIVs expressing
different Env proteins in a total volume of 100 ml were added to wells so that the
final concentration of Maraviroc was 8 mM and AMD3100 1 mM. Medium was
changed 24 hr postinfection and 48 hr postinfection b-galactosidase activity
was determined using GalactoStar reagent (Applied Biosystems).
Animal Experiments
Rhesus macaques (Macaca mulatta) were housed and cared for in accor-
dance with American Association for Accreditation of Laboratory Animal
Care (AAALAC) standards in an AAALAC-accredited facility, and all animal
procedures were performed according to a protocol approved by the Institu-
tional Animal Care and Use Committee of the National Cancer Institute (see
also Supplemental Experimental Procedures). For infections with pooled viral
inocula, two macaques were inoculated with a cocktail of 21 SHIVs express-
ing group 1 Envs at a dose of 2.5 3 104 i.u. (as measured on TZM-bl) for each
virus (Figure 1A), and one macaque was inoculated with a cocktail of 16
SHIVs expressing group 2 Envs, at a dose of 5 3 104 i.u. for each virus (Fig-
ure 1B). Inoculations were performed intravenously (saphenous vein), and the
animals were subjected to CD8+ cell depletion by subcutaneous administra-
tion of a chimeric ‘‘rhesusized’’ anti-CD8 mAb, M-T807R1 (obtained from
Keith Reimann, NIAID NHP Reagent Program, Harvard/Beth Israel Deaconess
Medical Center) at a dose of 25 mg/kg, 30 min prior to virus inoculation and
again 1 week later.
Virus inoculations with individual SHIVs were performed intravenously in
macaques that were not CD8+ cell depleted. Two animals each received
2.9 3 105 i.u. of SHIVAD081 (Figure 3A), and two animals each received 4.8 3
105 i.u. of SHIV1054 (Figure 3B).
Six animals were inoculated intrarectally using increasing doses of SHIV1054
(Figure 3C). The specific doses usedwere 33 103 i.u. at week 0 and 33 104 i.u.
at week 6 for TI-1, 3 3 104 i.u. at week 0 and 7.3 3 104 i.u. at week 3 for TI-2,
33 104 i.u. at week 0, 7.33 104 i.u. at week 3 and 2.13 105 i.u. at week 8 for TI-
3, 33 103 i.u. at week 0 and 2.13 105 i.u. at week 14.4 for TI-4, and 2.13 105
i.u. at week 0 for TI-5 and TI-6.
For immunoprophylactic studies, six macaques received 10 mg/kg of
PGT121 and six the control antibody DEN3 (Moldt et al., 2012) via intravenous
infusion. All animals were subsequently inoculated intrarectally with 2.1 3 105
i.u. of SHIV1054 at 24 hr post-antibody infusion.
GALT Biopsies
Pinch biopsies of lower duodenal/upper jejunal tissue (up to 15 pinches per
procedure, approximately 2 to 3 mm3) were obtained using biopsy forceps
under direct endoscopic visualization from macaques under isoflurane
anesthesia. For flow cytometry analysis, mononuclear cells were obtained
from biopsy specimens processed using mechanical disruption and enzymicsevier Inc.
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Transmitted/Founder SHIVsdigestion of connective tissues, as previously described (Lifson et al., 2003;
Veazey et al., 2001).
Viral Load Measurements
Virions were pelleted from plasma and virion-associated RNA extracted, as
described previously (Cline et al., 2005). Briefly, plasma viral load was quanti-
fied using a two-step real-time qRT-PCR based on amplification of an SIV-
mac239-derived sequence located in the Gag coding region.
Single-Genome Amplification/Sequencing of SHIV env
A viral DNA fragment that includes the entire env gene was amplified from
the inoculum stock and each macaque at peak viremia using limiting dilution,
single-genome amplification PCR approach. For details, see Supplemental
Experimental Procedures.
Flow Cytometry
Antibodies and reagents were obtained fromBDBiosciences, unless indicated
otherwise, and data analysis was performed using FCS Express (De Novo
Software). Samples were prepared and absolute cell counting and lymphocyte
immunophenotyping were performed as previously described (Del Prete et al.,
2012; Hatziioannou et al., 2009; Tabb et al., 2013). For details, see Supple-
mental Experimental Procedures.
Cell-Associated Viral RNA and DNA
A hybrid real-time/digital PCR format and analysis approach, previously
described (Hansen et al., 2011), was applied for determination of cell-associ-
ated viral loads in isolated PBMCs. Quantitative hybrid real-time/digital nested
PCR were performed as previously described (Hansen et al., 2011). A total of
12 replicates of each DNA or RNA sample were tested with two of the repli-
cates containing a spike of DNA or RNA standard, as appropriate, to monitor
assay performance and to guide retest requirements. Determined SIV DNA
and RNA values were normalized to cell equivalents determined from coampli-
fication of a target sequence in the Rhesus CCR5 gene sequence present at
single haploid copy per genome.
Neutralization Tier Phenotyping and Neutralization Assays
Neutralization tier phenotyping of the R5-SHIVs was performed using TZM-bl
cells as described previously (Li et al., 2005). Neutralization titers are the sam-
ple dilution (for plasma) or antibody concentration (for sCD4, purified IgG prep-
arations and monoclonal antibodies) at which relative luminescence units
(RLUs) were reduced by 50%compared to RLU in virus control wells after sub-
traction of background RLU in cell control wells.
Serum neutralizing titers against the challenge SHIV1054 stock of animals
infusedwith PGT121were determined in TZM-bl cells, as previously described
(Li et al., 2005). Briefly, virus was mixed with serial dilution of the serum sam-
ples starting at 100-fold dilution. Following 1 hr of incubation, the virus/serum
mix was used to infect TZM-bl cells Forty-eight hours after infection, the cells
were lysed, and luciferase expression was evaluated using the Bright-Glo lucif-
erase assay (Promega).
ELISA Assays
PGT121 serum concentration was determined by a recombinant HIVJRFL
gp120-specific (Progenics Pharmaceuticals) ELISA, as previously described
(Parren et al., 2001). Briefly, microtiter plates were coated overnight with
2 mg/ml HIVJRFL gp120. Following a wash step, the plates were blocked for
1 hr with 3% (vol/vol) BSA and incubated for 2 hr with serial dilution of the
serum samples starting at 20-fold dilution or control antibodies. Binding was
detected with a goat anti-human IgG F(ab)2 fragment coupled to alkaline
phosphatase (Pierce) and visualized with p-nitrophenyl phosphate substrate
(Sigma-Aldrich).
Immunoblot Analyses
SHIV1054 virions generated in transfected 293T cells were purified by centrifu-
gation through sucrose and resuspended in PBS. Following initial densitom-
etry determination of capsid (CA) protein concentration in samples run on
Coomassie-stained gels, 200 ng CA/lane were loaded and separated on
4%–20% acrylamide gradient gels. Proteins were then transferred onto a
PVDF membrane (Millipore Immobilon-P, IPVH00010) using a semi-dry elec-Cell Host & Mtroblotter (Ellard Instrumentation), cut into strips, and probed with heat-inacti-
vated plasma from infected macaques clarified by centrifugation and diluted
1:1,000, followed by a goat anti-human IgG-peroxidase conjugate (Sigma
cat. #A8667) diluted 1:10,000. Blots were developed using chemiluminescent
detection reagents (Pierce).
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